2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

© 2017 American Association for the Advancement of Science. All rights Reserved. AAAS is a partner of HINARI, AGORA, OARE, CHORUS, CLOCKSS, CrossRef and COUNTER.

        Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our current

RSUs. We have granted RSUs to certain of our Office Holders. Such award agreements may contain acceleration provisions upon certain merger, acquisition, or change of control transactions. See also “Item 6. Directors, Senior Management and Employees—E. Share Ownership.” We describe our 2013 Plan under “Item 6. Directors, Senior Management and Employees—B. Compensation—2013 Incentive Share Option Plan.” If the relationship between us and an Office Holder is terminated, RSUs that are vested shall be settled in accordance with the settlement schedule set forth in the applicable award agreement.

        Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources, including management time and financial resources, and may not be successful. If any of our product candidates is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:

        The Company has derived all of its revenue to date from its collaboration agreement with Merck (the "Merck Agreement"). Refer to Note 7, "Revenue Recognition." The Merck Agreement is accounted for under ASC 606 since it does not represent a collaborative arrangement under ASC 808, "Collaborative Arrangements," as the Company is not an active participant and is not exposed to significant risks and rewards of the arrangement.

To better understand the role of Aramchol in NASH, we analyzed the effect of Aramchol in MCD diet model. The aim of this study was to investigate Aramchol’s mechanism of action and its effect on fibrosis using the methionine- and choline-deficient (MCD) diet model of NASH. We collected liver and serum from mice fed a MCD diet containing 0.1% methionine (0.1MCD) for four weeks, which developed steatohepatitis and fibrosis, as well as mice receiving a control diet; the metabolomes and proteomes were determined. 0.1MCD fed mice were given Aramchol (5mg/kg/day for the last 2 weeks); liver samples were analyzed histologically. Aramchol administration was found to reduce features of steatohepatitis and fibrosis in 0.1MCD fed mice. Aramchol downregulated the SCD1 enzyme, a key enzyme involved in triglyceride biosynthesis whose loss enhances fatty acid β-oxidation. In addition, Aramchol increased the flux through the transsulfuration pathway, leading to a rise in glutathione (GSH) and GSH/GSSG ratio, the main cellular antioxidant that maintains intracellular redox status. Comparison of the serum metabolomic pattern between 0.1MCD-fed mice and patients with NAFLD showed a substantial overlap. These findings were published in Hepatology Communications, Vol. 1, No. 9, 2017.

All mice and rats were cared for in accordance with the University of Illinois at Chicago Animal Care Policy following the Guide for the Care and Use of Laboratory Animals. All animal experimental protocols were reviewed and approved by the Institutional Animal Care and Use Committee at the University of Illinois at Chicago. Chronic hypoxia exposure: Two-month-old adult C57/BL6 mice and Sprague-Dawley rats were exposed to normobaric hypoxia for different time intervals (2, 7, 14, and 21 days) in a plexiglass chamber provided with an oxygen controller by infusing nitrogen gas to maintain 10% oxygen (balance nitrogen; FiO2 0.10) (BioSpherix, Lacona, NY) as described before22. Lung tissues from the PAH mice were stored at −80 °C for subsequent quantitative RT-PCR analyses.

        Eculizumab is approved for the treatment of refractory MG in Europe and Japan and for the treatment of gMG in the U.S. Eculizumab is a monoclonal antibody that binds C5 and prevents its cleavage to C5a and C5b, thus blocking a key step in the complement activation pathway. Eculizumab is administered intravenously by healthcare professionals at bi-weekly intervals.

The discussion is not about whether or not the life could be prolonged. Certainly, it could. We are talking about whether the maximal life could be significantly prolonged. For example for the House mouse, the maximal lifespan is 4 years. If there could be genetically manipulated (or otherwise) that a mouse could live more than 6 years then we could speak about the pushing up the limit

In the annual general meeting to be convened in 2019, our Board plans to nominate Mr. Baharaff and Mr. Heinberg for re-election to serve as Class II Directors until the close of the annual general meeting to be held in 2022 and nominate Prof. Oren for re-election to serve as a Class III Director until the close of the annual general meeting to be held in 2020.

Alliance Pharma plc (LSE:APH.L ) is a specialty pharmaceutical group based in the United Kingdom and listed on AIM. Alliance now owns or licenses over 50 prescription products.